Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases
NCT06986369
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
140
Enrollment
OTHER
Sponsor class
Conditions
Atherosclerosis, Coronary
Interventions
DRUG:
Rivaroxaban 2.5 MG Oral Tablet [Xarelto]
Sponsor
The University of Hong Kong
Collaborators
[object Object]